Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Its biologics license application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma is under review by the FDA. Its LYMPHIR also received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, the company is developing CITI-002 (Halo-Lido), which is in Phase 2b trial for the relief of hemorrhoids. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
| 0.96 | |
| 0.9561 | |
| - | |
| 0.96 | |
| 0.92 | |
| 0.48-1.07 | |
| 167 M | |
| 181 M | |
| 0 | |
| -0.05 | |
| 1.682 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transac...
No clinical efficacy or safety issues raised Citius committed to working toward approval CRANFORD, N.J., July 29, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasda...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
